EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase II)Multizentrische StudieOpen Access

BCG Revaccination for the Prevention of Mycobacterium tuberculosis Infection

Alexander C Schmidt, Lee Fairlie, Elizabeth Hellström, Angelique Luabeya Kany Kany, Keren Middelkoop, Kogieleum Naidoo, Gonasagrie Nair, Anele Gela, Elisa Nemes, Thomas J Scriba, Amy Cinar, Nicole Frahm und 5 weitere

New England Journal of Medicine · 08.05.2025 · 392 (18) · 1789-1800

DOI: 10.1056/nejmoa2412381 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift New England Journal of Medicine, erschienen am 08.05.2025. Verfasst von Alexander C Schmidt und 16 weiteren Autor:innen. Beteiligte Einrichtung: Gates Medical Research Institute, Cambridge, MA. Hauptthemen laut MEDLINE: BCG Vaccine, Immunization, Secondary, Mycobacterium tuberculosis, Tuberculosis. Die Arbeit wurde bisher 68-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BCG VaccineImmunization, SecondaryMycobacterium tuberculosisTuberculosisVaccine EfficacyAdolescentChildFemaleHumansMaleDouble-Blind MethodIntention to Treat AnalysisInterferon-gamma Release TestsFollow-Up StudiesInjection Site ReactionT-Lymphocytes, Helper-InducerTreatment OutcomeIncidenceSouth Africa

Substanzen

BCG Vaccine

Autor:innen und Institutionen

  • Gates Medical Research Institute, Cambridge, MA.
  • Wits Reproductive Health and HIV Institute, University of Witwatersrand, Johannesburg.
  • Be Part Yoluntu Centre, Paarl, South Africa.
  • South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine and Department of Pathology, University of Cape Town, Cape Town, South Africa.
  • Desmond Tutu HIV Centre, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.
  • South African Medical Research Council HIV-TB Pathogenesis and Treatment Research Unit, Centre for the AIDS Programme of Research in South Africa, Durban.

ORCID-Profile: Mark Hatherill

Zitieren

APA

Schmidt, A. C., Fairlie, L., Hellström, E., Luabeya Kany Kany, A., Middelkoop, K., Naidoo, K., Nair, G., Gela, A., Nemes, E., Scriba, T. J., Cinar, A., Frahm, N., Mogg, R., Kaufman, D., Dunne, M. W., Hatherill, M., & BCG REVAX Study Team (2025). BCG Revaccination for the Prevention of Mycobacterium tuberculosis Infection. New England Journal of Medicine, 392(18), 1789-1800. https://doi.org/10.1056/nejmoa2412381

Vancouver

Schmidt AC, Fairlie L, Hellström E, Luabeya Kany Kany A, Middelkoop K, Naidoo K, et al. BCG Revaccination for the Prevention of Mycobacterium tuberculosis Infection. New England Journal of Medicine. 2025;392(18):1789-1800. doi:10.1056/nejmoa2412381

BibTeX
@article{Schmidt2025,
  author = {Schmidt, Alexander C and Fairlie, Lee and Hellström, Elizabeth and Luabeya Kany Kany, Angelique and Middelkoop, Keren and Naidoo, Kogieleum and Nair, Gonasagrie and Gela, Anele and Nemes, Elisa and Scriba, Thomas J and Cinar, Amy and Frahm, Nicole and Mogg, Robin and Kaufman, David and Dunne, Michael W and Hatherill, Mark and BCG REVAX Study Team, BCG REVAX Study Team},
  title = {BCG Revaccination for the Prevention of Mycobacterium tuberculosis Infection},
  journal = {New England Journal of Medicine},
  year = {2025},
  volume = {392},
  number = {18},
  pages = {1789--1800},
  doi = {10.1056/nejmoa2412381}
}
Kostenlos starten →